2 recruiting, 1 completed, 1 terminated, 1 unknown. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Recruiting 2, Completed 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Polypoidal Choroidal Vasculopathy: new trials by email Literature Review of Polypoidal Choroidal Vasculopathy trials Research Report on Polypoidal Choroidal Vasculopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial aflibercept 8 mg - Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-12-24 | 2026-02-05 |
| Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-03-01 | 2026-03-10 |
| Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Brolucizumab 6mg - Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2023-02-06 | 2025-12-15 |
| Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose - Polypoidal Choroidal Vasculopathy | Phase 2 / Phase 3 | Terminated | Sun Yat-sen University | 5 | 2018-08-01 | 2019-09-19 |
| Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Bevacizumab (tradename: Avastin) - Choroidal Neovascularisation, Polypoidal Choroidal Vasculopathy | Phase 3 | Unknown | Singapore National Eye Centre | 50 | 2006-06-01 | 2007-09-26 |
Choroidal Neovascularization (1) · Eye Diseases (1) · Macular Degeneration (1) · Retinal Diseases (1) · Scotoma (1) · Vascular Diseases (1)
Choroid Diseases (5) · Metaplasia (5) · Neovascularization, Pathologic (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Uveal Diseases (5) · Choroidal Neovascularization (4) · Eye Diseases (4) · Cardiovascular Diseases (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Sensation Disorders (1) · Signs and Symptoms (1)
Bevacizumab (1) · Ranibizumab (1) · aflibercept (1) · brolucizumab (1) · faricimab (1)
Yeungnam University College of Medicine (2) · Novartis Pharmaceuticals (1) · Singapore National Eye Centre (1) · Sun Yat-sen University (1)
South Korea (3) · China (1)
Chong-Lye Ang, FRCOphth (1) · Lin Lu, MD, phD (1)
PMID 14557174, PMID 16897221, PMID 19726427, PMID 22426346, PMID 23352196, PMID 25646029